Back بيتاهستين Arabic بتاهیستین AZB Betahistin German Betahistina Spanish Betahistina Basque بتاهیستین Persian Betahistiini Finnish Bétahistine French בטאהיסטין HE Betahisztin Hungarian
 | This article needs additional citations for verification. (September 2016) |
 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Serc, others |
| AHFS/Drugs.com | International Drug Names |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | ~100%[1] |
| Protein binding | <5%[1] |
| Metabolism | Liver[1] |
| Metabolites | • 2-(2-Aminoethyl)pyridine • 2-Pyridylacetic acid[1] |
| Onset of action | <1 hour (peak)[2] |
| Elimination half-life | 3.5 hours[3] |
| Excretion | Urine: 91%[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.024.625 |
| Chemical and physical data | |
| Formula | C8H12N2 |
| Molar mass | 136.198 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Betahistine, sold under the brand name Serc among others, is an anti-vertigo medication. It is commonly prescribed for balance disorders or to alleviate vertigo symptoms. It was first registered in Europe in 1970 for the treatment of Ménière's disease, but current evidence does not support its efficacy in treating it.[4][5]
- ^ a b c d e Dickenson A (2017). Drugs in Neurology. Oxford University Press. pp. 408–409. ISBN 978-0-19-966436-8.
- ^ White R, Bradnam V (2015). Handbook of Drug Administration via Enteral Feeding Tubes (3rd ed.). Pharmaceutical Press. pp. 125–. ISBN 978-0-85711-162-3.
- ^ Tiziani AP (2013). Havard's Nursing Guide to Drugs. Elsevier Health Sciences. pp. 1063–. ISBN 978-0-7295-8162-2.
- ^ James AL, Burton MJ (2001). "Betahistine for Menière's disease or syndrome". The Cochrane Database of Systematic Reviews. 2001 (1): CD001873. doi:10.1002/14651858.CD001873. PMC 6769057. PMID 11279734.
- ^ Adrion C, Fischer CS, Wagner J, Gürkov R, Mansmann U, Strupp M (January 2016). "Efficacy and safety of betahistine treatment in patients with Meniere's disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial)". BMJ. 352: h6816. doi:10.1136/bmj.h6816. PMC 4721211. PMID 26797774.